Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

SF 2319

1st Engrossment - 87th Legislature (2011 - 2012) Posted on 04/04/2012 08:44am

KEY: stricken = removed, old language.
underscored = added, new language.
Line numbers 1.1 1.2 1.3 1.4 1.5 1.6 1.7
1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 2.33 2.34 2.35 2.36 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 3.31 3.32 3.33 3.34 3.35 3.36 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 4.31 4.32 4.33 4.34 4.35 4.36 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 5.21 5.22 5.23 5.24 5.25 5.26 5.27 5.28 5.29 5.30 5.31 5.32 5.33 5.34 5.35 5.36 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 6.10 6.11 6.12 6.13 6.14 6.15 6.16 6.17 6.18 6.19 6.20 6.21 6.22 6.23 6.24 6.25 6.26 6.27 6.28 6.29 6.30 6.31 6.32 6.33 6.34 6.35 6.36 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 7.22 7.23 7.24 7.25 7.26 7.27 7.28 7.29 7.30 7.31 7.32 7.33 7.34 7.35 7.36 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.11 8.12 8.13 8.14 8.15 8.16 8.17 8.18 8.19 8.20 8.21 8.22 8.23 8.24 8.25 8.26 8.27 8.28 8.29 8.30 8.31 8.32 8.33 8.34 8.35 8.36 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 9.10 9.11 9.12 9.13 9.14 9.15 9.16 9.17 9.18 9.19 9.20 9.21 9.22 9.23 9.24 9.25 9.26 9.27 9.28 9.29 9.30 9.31 9.32 9.33 9.34 9.35 9.36 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 10.10 10.11 10.12 10.13 10.14 10.15 10.16 10.17 10.18 10.19 10.20 10.21 10.22 10.23 10.24 10.25 10.26 10.27 10.28 10.29 10.30 10.31 10.32 10.33 10.34 10.35 10.36 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 11.10 11.11 11.12 11.13 11.14 11.15 11.16 11.17 11.18 11.19 11.20 11.21 11.22 11.23 11.24 11.25 11.26 11.27 11.28 11.29 11.30 11.31 11.32 11.33 11.34 11.35 11.36 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 12.10 12.11 12.12 12.13 12.14 12.15 12.16 12.17 12.18 12.19 12.20 12.21 12.22 12.23 12.24 12.25 12.26 12.27 12.28 12.29 12.30 12.31 12.32 12.33 12.34 12.35 12.36 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 13.9 13.10 13.11 13.12 13.13 13.14 13.15 13.16 13.17 13.18 13.19 13.20 13.21 13.22 13.23 13.24 13.25 13.26 13.27 13.28 13.29 13.30 13.31 13.32 13.33 13.34 13.35 13.36 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 14.9 14.10 14.11 14.12 14.13 14.14 14.15 14.16 14.17 14.18 14.19 14.20 14.21 14.22 14.23 14.24 14.25 14.26 14.27 14.28 14.29 14.30 14.31 14.32 14.33 14.34 14.35 14.36 15.1 15.2 15.3 15.4 15.5 15.6 15.7 15.8 15.9 15.10 15.11 15.12 15.13 15.14 15.15 15.16 15.17 15.18 15.19 15.20 15.21 15.22 15.23 15.24 15.25 15.26 15.27 15.28 15.29 15.30 15.31 15.32 15.33 15.34 15.35 15.36 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 16.10 16.11 16.12 16.13 16.14 16.15 16.16 16.17 16.18 16.19 16.20 16.21 16.22 16.23 16.24 16.25 16.26 16.27 16.28 16.29 16.30 16.31 16.32 16.33 16.34 16.35 16.36 17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8 17.9 17.10 17.11 17.12 17.13 17.14 17.15 17.16 17.17 17.18 17.19 17.20 17.21 17.22 17.23 17.24 17.25 17.26 17.27 17.28 17.29 17.30 17.31 17.32 17.33 17.34 17.35 18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9 18.10 18.11 18.12 18.13 18.14 18.15 18.16 18.17 18.18 18.19 18.20 18.21 18.22 18.23 18.24 18.25 18.26 18.27 18.28 18.29 18.30 18.31 18.32 18.33 18.34 18.35 19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 19.10 19.11 19.12 19.13 19.14 19.15 19.16 19.17 19.18 19.19 19.20 19.21 19.22 19.23 19.24 19.25 19.26 19.27 19.28 19.29 19.30 19.31 19.32 19.33 19.34 19.35 19.36 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 20.10 20.11 20.12 20.13 20.14 20.15 20.16 20.17 20.18 20.19 20.20 20.21 20.22 20.23 20.24 20.25 20.26 20.27 20.28 20.29 20.30 20.31 20.32 20.33 20.34 20.35 20.36 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 21.9 21.10 21.11 21.12 21.13 21.14 21.15 21.16 21.17 21.18 21.19 21.20 21.21 21.22 21.23 21.24 21.25 21.26 21.27 21.28 21.29 21.30 21.31 21.32 21.33 21.34 21.35 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 22.10 22.11 22.12 22.13 22.14 22.15 22.16 22.17 22.18 22.19 22.20 22.21 22.22 22.23 22.24 22.25 22.26 22.27 22.28 22.29 22.30 22.31 22.32 22.33 22.34 22.35 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 23.10 23.11 23.12 23.13 23.14 23.15 23.16 23.17 23.18 23.19 23.20 23.21 23.22 23.23 23.24 23.25 23.26 23.27 23.28 23.29 23.30 23.31 23.32 23.33 23.34 23.35 24.1 24.2 24.3 24.4 24.5 24.6 24.7 24.8 24.9 24.10 24.11 24.12 24.13 24.14 24.15 24.16 24.17 24.18 24.19 24.20 24.21 24.22 24.23 24.24 24.25 24.26 24.27 24.28 24.29 24.30 24.31 24.32 24.33 24.34 24.35 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 25.9 25.10 25.11 25.12 25.13 25.14 25.15 25.16 25.17 25.18 25.19 25.20 25.21 25.22 25.23 25.24 25.25 25.26 25.27 25.28 25.29 25.30 25.31 25.32 25.33 25.34 25.35 25.36 26.1 26.2 26.3 26.4 26.5 26.6 26.7 26.8 26.9 26.10 26.11 26.12 26.13 26.14 26.15 26.16 26.17 26.18 26.19 26.20 26.21 26.22 26.23 26.24 26.25 26.26 26.27 26.28 26.29
26.30 26.31
26.32 26.33 27.1 27.2 27.3 27.4 27.5 27.6 27.7 27.8 27.9 27.10 27.11 27.12 27.13
27.14 27.15

A bill for an act
relating to public safety; aligning state-controlled substance schedules with
federal controlled substance schedules; modifying the authority of the Board of
Pharmacy to regulate controlled substances; providing for penalties; amending
Minnesota Statutes 2010, section 152.02, as amended; Minnesota Statutes 2011
Supplement, section 152.027, subdivision 6.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, chapter
53, sections 4 and 5, is amended to read:


152.02 SCHEDULES OF CONTROLLED SUBSTANCES;
ADMINISTRATION OF CHAPTER.

Subdivision 1.

Five schedules.

There are established five schedules of controlled
substances, to be known as Schedules I, II, III, IV, and V. deleted text beginSuchdeleted text end new text beginThe new text endschedules deleted text beginshall
initially
deleted text end consist of the substances listed in this section by whatever official name, common
or usual name, chemical name, or trade name designated.

Subd. 2.

Schedule I.

deleted text begin The following items are listed in Schedule I: deleted text end new text begin (a) Schedule I
consists of the substances listed in this subdivision.
new text end

deleted text begin (1)deleted text endnew text begin (b) Opiates. Unless specifically excepted or unless listed in another schedule,new text end
any of the following substances, including theirnew text begin analogs,new text end isomers, esters, ethers, salts, and
salts of isomers, esters, and ethers, deleted text beginunless specifically excepted,deleted text end whenever the existence
of thenew text begin analogs,new text end isomers, esters, ethers and salts is possible deleted text beginwithin the specific chemical
designation
deleted text end:

new text begin (1) new text endacetylmethadol;

new text begin (2) new text endallylprodine;

new text begin (3) new text endalphacetylmethadolnew text begin (except levo-alphacetylmethadol, also known as
levomethadyl acetate)
new text end;

new text begin (4) new text endalphameprodine;

new text begin (5) new text endalphamethadol;

new text begin (6) alpha-methylfentanyl new text endbenzethidine;

new text begin (7) new text endbetacetylmethadol;

new text begin (8) new text endbetameprodine;

new text begin (9) new text endbetamethadol;

new text begin (10) new text endbetaprodine;

new text begin (11) new text endclonitazene;

new text begin (12) new text enddextromoramide; deleted text begindextrorphan;
deleted text end

new text begin (13)new text end diampromide;

new text begin (14) new text enddiethyliambutene;

new text begin (15) difenoxin;new text end

new text begin (16) new text enddimenoxadol;

new text begin (17) new text enddimepheptanol;

new text begin (18) new text enddimethyliambutene;

new text begin (19) new text enddioxaphetyl butyrate;

new text begin (20) new text enddipipanone;

new text begin (21) new text endethylmethylthiambutene;

new text begin (22) new text endetonitazene;

new text begin (23) new text endetoxeridine;

new text begin (24) new text endfurethidine;

new text begin (25) new text endhydroxypethidine;

new text begin (26) new text endketobemidone;

new text begin (27) new text endlevomoramide;

new text begin (28) new text endlevophenacylmorphan;

new text begin (29) 3-methylfentanyl;
new text end

new text begin (30) acetyl-alpha-methylfentanyl;
new text end

new text begin (31) alpha-methylthiofentanyl;
new text end

new text begin (32) benzylfentanyl beta-hydroxyfentanyl;
new text end

new text begin (33) beta-hydroxy-3-methylfentanyl;
new text end

new text begin (34) 3-methylthiofentanyl;
new text end

new text begin (35) thenylfentanyl;
new text end

new text begin (36) thiofentanyl;
new text end

new text begin (37) para-fluorofentanyl;new text end

new text begin (38) new text endmorpheridine;

new text begin (39) 1-methyl-4-phenyl-4-propionoxypiperidine;new text end

new text begin (40) new text endnoracymethadol;

new text begin (41) new text endnorlevorphanol;

new text begin (42) new text end normethadone;

new text begin (43) new text endnorpipanone;

new text begin (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);new text end

new text begin (45) new text endphenadoxone;

new text begin (46) new text endphenampromide;

new text begin (47) new text endphenomorphan;

new text begin (48) new text endphenoperidine;

new text begin (49) new text endpiritramide;

new text begin (50) new text endproheptazine;

new text begin (51) new text endproperidine;

new text begin (52) propiram;new text end

new text begin (53) new text endracemoramide;

new text begin (54) tilidine;new text end

new text begin (55) new text endtrimeperidine.

deleted text begin (2)deleted text endnew text begin (c) Opium derivatives.new text end Any of the following deleted text beginopium derivativesdeleted text endnew text begin substancesnew text end,
theirnew text begin analogs,new text end salts, isomersnew text begin,new text end and salts of isomers, unless specifically exceptednew text begin or unless
listed in another schedule
new text end, whenever the existence of thenew text begin analogs,new text end salts, isomers and salts
of isomers is possible deleted text beginwithin the specific chemical designationdeleted text end:

new text begin (1) new text endacetorphine;

new text begin (2) new text endacetyldihydrocodeine; deleted text beginacetylcodone;deleted text end

new text begin (3) new text endbenzylmorphine;

new text begin (4) new text endcodeine methylbromide;

new text begin (5) new text endcodeine-n-oxide;

new text begin (6) new text endcyprenorphine;

new text begin (7) new text enddesomorphine;

new text begin (8) new text enddihydromorphine;

new text begin (9) new text endnew text begin drotebanol;new text end

new text begin (10) new text endetorphine;

new text begin (11) new text endheroin;

new text begin (12) new text endhydromorphinol;

new text begin (13) new text endmethyldesorphine; deleted text beginmethylhydromorphine
deleted text end

new text begin (14) methyldihydromorphinenew text end;

new text begin (15) new text endmorphine methylbromide;

new text begin (16) new text endmorphine methylsulfonate;

new text begin (17) new text endmorphine-n-oxide;

new text begin (18) new text endmyrophine;

new text begin (19) new text endnicocodeine;

new text begin (20) new text endnicomorphine;

new text begin (21) new text endnormorphine;

new text begin (22) new text endpholcodine;

new text begin (23) new text endthebacon.

deleted text begin (3)deleted text endnew text begin (d)new text endnew text begin Hallucinogens.new text end Any material, compound, mixture or preparation which
contains any quantity of the following deleted text beginhallucinogenicdeleted text end substances, theirnew text begin analogs,new text end salts,
isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically
excepted or unless listed in another schedule, whenever the existence of thenew text begin analogs,new text end salts,
isomers, and salts of isomers is possible:

deleted text begin 3,4-methylenedioxy amphetaminedeleted text endnew text begin (1) methylenedioxy amphetaminenew text end;

deleted text begin 3,4-methylenedioxymethamphetaminedeleted text endnew text begin (2) methylenedioxymethamphetaminenew text end;

new text begin (3) methylenedioxy-N-ethylamphetamine (MDEA);
new text end

new text begin (4) n-hydroxy-methylenedioxyamphetamine;new text end

new text begin (5) new text end4-bromo-2,5-dimethoxyamphetaminenew text begin (DOB)new text end;

new text begin (6) new text end2,5-dimethoxyamphetaminenew text begin (2,5-DMA)new text end;

new text begin (7) new text end4-methoxyamphetamine;

new text begin (8) new text end5-methoxy-3, 4-methylenedioxy amphetamine;

new text begin (9) alpha-ethyltryptamine;new text end

new text begin (10) new text endbufotenine;

new text begin (11) new text enddiethyltryptamine;

new text begin (12) new text enddimethyltryptamine;

new text begin (13) new text end3,4,5-trimethoxy amphetamine;

new text begin (14) new text end4-methyl-2, 5-dimethoxyamphetaminenew text begin (DOM)new text end;

new text begin (15) new text endibogaine;

new text begin (16) new text endlysergic acid diethylamidenew text begin (LSD)new text end; deleted text beginmarijuana;deleted text end

new text begin (17) new text endmescaline;

new text begin (18) parahexyl;new text end

new text begin (19) new text endN-ethyl-3-piperidyl benzilate;

new text begin (20) new text endN-methyl-3-piperidyl benzilate;

new text begin (21) new text endpsilocybin;

new text begin (22) new text endpsilocyn;

deleted text begin Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidinedeleted text endnew text begin (23) tenocyclidine
(TPCP or TCP)
new text end;

new text begin (24) new text endN-ethyl-1-phenyl-cyclohexylaminenew text begin (PCE)new text end;

new text begin (25) new text end1-(1-phenylcyclohexyl) pyrrolidinenew text begin (PCPy);
new text end

new text begin (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
new text end

new text begin (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
new text end

new text begin (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
new text end

new text begin (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
new text end

new text begin (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
new text end

new text begin (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
new text end

new text begin (32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD)new text end;

deleted text begin 2,5-dimethoxy-4-ethylphenethylamine, also known asdeleted text endnew text begin (33)
4-ethyl-2,5-dimethoxyphenethylamine (
new text end2C-Enew text begin)new text end;

deleted text begin 2,5-dimethoxy-4-iodophenethylamine, also known asdeleted text end new text begin(34)
4-iodo-2,5-dimethoxyphenethylamine (
new text end2C-Inew text begin);
new text end

new text begin (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
new text end

new text begin (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
new text end

new text begin (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
new text end

new text begin (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
(2-CB-FLY);
new text end

new text begin (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
new text end

new text begin (40) alpha-methyltryptamine (AMT);
new text end

new text begin (41) N,N-diisopropyltryptamine (DiPT);
new text end

new text begin (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
new text end

new text begin (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
new text end

new text begin (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
new text end

new text begin (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
new text end

new text begin (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
new text end

new text begin (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
new text end

new text begin (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
new text end

new text begin (49) 5-methoxy-?-methyltryptamine (5-MeO-AMT);
new text end

new text begin (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
new text end

new text begin (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
new text end

new text begin (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
new text end

new text begin (53) 5-methoxy-?-ethyltryptamine (5-MeO-AET);
new text end

new text begin (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
new text end

new text begin (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
new text end

new text begin (56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
new text end

new text begin (57) methoxetamine (MXE);
new text end

new text begin (58) 5-iodo-2-aminoindane (5-IAI);
new text end

new text begin (59) 5,6-methylenedioxy-2-aminoindane (MDAI)new text end.

deleted text begin (4)deleted text endnew text begin (e)new text end Peyotedeleted text begin, providingdeleted text endnew text begin.new text endnew text begin All parts of the plant presently classified botanically as
Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract
from any part of the plant, and every compound, manufacture, salts, derivative, mixture,
or preparation of the plant, its seeds or extracts.
new text end The listing of peyote as a controlled
substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious
ceremonies of the American Indian Church, and members of the American Indian Church
are exempt from registration. Any person who manufactures peyote for or distributes
peyote to the American Indian Church, however, is required to obtain federal registration
annually and to comply with all other requirements of law.

deleted text begin (5)deleted text endnew text begin (f) Central nervous system depressants.new text end Unless specifically excepted or unless
listed in another schedule, any material compound, mixture, or preparation which contains
any quantity of the following substances deleted text beginhaving a depressant effect on the central nervous
system, including its
deleted text endnew text begin, their analogs,new text end salts, isomers, and salts of isomers whenever the
existence of thenew text begin analogs,new text end salts, isomers, and salts of isomers is possible deleted text beginwithin the specific
chemical designation
deleted text end:

new text begin (1) new text endmecloqualone;

new text begin (2) methaqualone;
new text end

new text begin (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
new text end

new text begin (4) new text endflunitrazepam.

deleted text begin (6)deleted text endnew text begin (g) Stimulants.new text end Unless specifically excepted or unless listed in another schedule,
any material compound, mixture, or preparation which contains any quantity of the
following substances deleted text beginhaving a stimulant effect on the central nervous system, including itsdeleted text endnew text begin,
their analogs,
new text end salts, isomers, and salts of isomers whenever the existence of thenew text begin analogs,new text end
salts, isomers, and salts of isomers is possible deleted text beginwithin the specific chemical designationdeleted text end:

new text begin (1) aminorex;
new text end

new text begin (2) new text endcathinone;

new text begin (3) fenethylline;
new text end

new text begin (4) new text endmethcathinone;

new text begin (5) methylaminorex;
new text end

new text begin (6) N,N-dimethylamphetamine;
new text end

new text begin (7) N-benzylpiperazine (BZP);new text end

deleted text begin 4-methylmethcathinonedeleted text endnew text begin (8) methylmethcathinonenew text end (mephedrone);

new text begin (9) new text end3,4-methylenedioxy-N-methylcathinone (methylone);

deleted text begin 4-methoxymethcathinonedeleted text endnew text begin (10) methoxymethcathinonenew text end (methedrone);

deleted text begin 3,4 - methylenedioxypyrovaleronedeleted text endnew text begin (11) methylenedioxypyrovalerone new text end (MDPV)new text begin;
new text end

new text begin (12) fluoromethcathinone;
new text end

new text begin (13) methylethcathinone (MEC);
new text end

new text begin (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
new text end

new text begin (15) dimethylmethcathinone (DMMC);
new text end

new text begin (16) fluoroamphetamine;
new text end

new text begin (17) fluoromethamphetamine;
new text end

new text begin (18) ?-methylaminobutyrophenone (MABP or buphedrone);
new text end

new text begin (19) ?-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
new text end

new text begin (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
new text end

new text begin (21) naphthylpyrovalerone (naphyrone);
new text end

new text begin (22) and any other substance, except bupropion or compounds listed under a
different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
the compound is further modified in any of the following ways:
new text end

new text begin (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
system by one or more other univalent substituents;
new text end

new text begin (ii) by substitution at the 3-position with an acyclic alkyl substituent;
new text end

new text begin (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
methoxybenzyl groups; or
new text end

new text begin (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structurenew text end.

deleted text begin (7)deleted text endnew text begin (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids.new text end Unless
specifically excepted or unless listed in another schedule, any natural or synthetic material,
compound, mixture, or preparation that contains any quantity of deleted text begina substance that is a
cannabinoid receptor agonist, including, but not limited to,
deleted text end the following substances deleted text beginanddeleted text endnew text begin,new text end
their analogs, deleted text beginincludingdeleted text end isomers, deleted text beginwhether optical, positional, or geometric;deleted text end estersdeleted text begin;deleted text endnew text begin,new text end ethersdeleted text begin;deleted text endnew text begin,new text end
saltsdeleted text begin;deleted text endnew text begin,new text end and salts of isomers, esters, and ethers, whenever the existence of the isomers,
esters, ethers, or salts is possible deleted text beginwithin the specific chemical designationdeleted text end:

deleted text begin 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015),
1-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole
(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073),
4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081),
4-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone
(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone
(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203),
4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210),
2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250),
1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)-
9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3-
(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497),
dimethylheptylpyran.
deleted text end

new text begin (1) marijuana;
new text end

new text begin (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
synthetic equivalents of the substances contained in the cannabis plant or in the
resinous extractives of the plant, or synthetic substances with similar chemical structure
and pharmacological activity to those substances contained in the plant or resinous
extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
new text end

new text begin (3) synthetic cannabinoids, including the following substances:
new text end

new text begin (i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
extent and whether or not substituted in the naphthyl ring to any extent. Examples of
naphthoylindoles include, but are not limited to:
new text end

new text begin (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
new text end

new text begin (B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
new text end

new text begin (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
new text end

new text begin (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
new text end

new text begin (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
new text end

new text begin (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
new text end

new text begin (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
new text end

new text begin (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
new text end

new text begin (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
new text end

new text begin (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
new text end

new text begin (ii) Napthylmethylindoles, which are any compounds containing a
1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
substituted in the indole ring to any extent and whether or not substituted in the naphthyl
ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
new text end

new text begin (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
new text end

new text begin (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
new text end

new text begin (iii) Naphthoylpyrroles, which are any compounds containing a
3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
further substituted in the pyrrole ring to any extent, whether or not substituted in the
naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
new text end

new text begin (iv) Naphthylmethylindenes, which are any compounds containing a
naphthylideneindene structure with substitution at the 3-position of the indene
ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
substituted in the indene ring to any extent, whether or not substituted in the naphthyl
ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
new text end

new text begin (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
any extent, whether or not substituted in the phenyl ring to any extent. Examples of
phenylacetylindoles include, but are not limited to:
new text end

new text begin (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
new text end

new text begin (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
new text end

new text begin (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
new text end

new text begin (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
new text end

new text begin (vi) Cyclohexylphenols, which are compounds containing a
2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
but are not limited to:
new text end

new text begin (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
new text end

new text begin (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
(Cannabicyclohexanol or CP 47,497 C8 homologue);
new text end

new text begin (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
-phenol (CP 55,940).
new text end

new text begin (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
any extent and whether or not substituted in the phenyl ring to any extent. Examples of
benzoylindoles include, but are not limited to:
new text end

new text begin (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
new text end

new text begin (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
new text end

new text begin (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
(WIN 48,098 or Pravadoline).
new text end

new text begin (viii) Others specifically named:
new text end

new text begin (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
new text end

new text begin (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
new text end

new text begin (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).
new text end

deleted text begin (8)deleted text endnew text begin (i)new text end A controlled substance analog, to the extent that it is implicitly or explicitly
intended for human consumption.

Subd. 3.

Schedule II.

deleted text beginThe following items are listed indeleted text endnew text begin (a)new text end Schedule IIdeleted text begin:deleted text endnew text begin consists of
the substances listed in this subdivision.
new text end

deleted text begin (1)deleted text endnew text begin (b)new text end Unless specifically excepted or unless listed in another schedule, any of
the following substances whether produced directly or indirectly by extraction from
substances of vegetable origin or independently by means of chemical synthesis, or by a
combination of extraction and chemical synthesis:

deleted text begin (a)deleted text endnew text begin (1)new text end Opium and opiate, and any salt, compound, derivative, or preparation
of opium or opiatedeleted text begin, including the following: raw opium, opium extracts, opium
fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine,
codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone,
oxymorphone, thebaine
deleted text end.

new text begin (i) Excluding:
new text end

new text begin (A) apomorphine;
new text end

new text begin (B) thebaine-derived butorphanol;
new text end

new text begin (C) dextrophan;
new text end

new text begin (D) nalbuphine;
new text end

new text begin (E) nalmefene;
new text end

new text begin (F) naloxone;
new text end

new text begin (G) naltrexone;
new text end

new text begin (H) and their respective salts;
new text end

new text begin (ii) but including the following:
new text end

new text begin (A) opium, in all forms and extracts;
new text end

new text begin (B) codeine;
new text end

new text begin (C) dihydroetorphine;
new text end

new text begin (D) ethylmorphine;
new text end

new text begin (E) etorphine hydrochloride;
new text end

new text begin (F) hydrocodone;
new text end

new text begin (G) hydromorphone;
new text end

new text begin (H) metopon;
new text end

new text begin (I) morphine;
new text end

new text begin (J) oxycodone;
new text end

new text begin (K) oxymorphone;
new text end

new text begin (L) thebaine;
new text end

new text begin (M) oripavine;
new text end

deleted text begin (b)deleted text endnew text begin (2)new text end any salt, compound, derivative, or preparation thereof which is chemically
equivalent or identical with any of the substances referred to in clause deleted text begin(a)deleted text endnew text begin (1)new text end, except that
these substances shall not include the isoquinoline alkaloids of opiumdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (c)deleted text endnew text begin (3)new text end opium poppy and poppy strawdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (d)deleted text endnew text begin (4)new text end coca leaves and any salt,new text begin cocainenew text end compound, derivative, or preparation
of coca leaves, deleted text beginincluding cocaine and ecgonine, the salts and isomers of cocaine and
ecgonine, and the salts of their isomers.
deleted text endnew text begin (including cocaine and ecgonine and their salts,
isomers, derivatives, and salts of isomers and derivatives), and any salt, compound,
derivative, or preparation thereof which is chemically equivalent or identical with any of
these substances, except that the substances shall not include decocainized coca leaves or
extraction of coca leaves, which extractions do not contain cocaine or ecgonine;
new text end

deleted text begin (e) Any salt, compound, derivative, or preparation thereof which is chemically
equivalent or identical with any of the substances referred to in clause (d), except that
the substances shall not include decocainized coca leaves or extraction of coca leaves,
which extractions do not contain cocaine or ecgonine.
deleted text end new text begin (5) concentrate of poppy straw (the
crude extract of poppy straw in either liquid, solid, or powder form which contains the
phenanthrene alkaloids of the opium poppy).
new text end

deleted text begin (2)deleted text endnew text begin (c)new text end Any of the following opiates, including their isomers, esters, ethers, salts, and
salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
schedule, whenever the existence of such isomers, esters, ethers and salts is possible
within the specific chemical designation:

new text begin (1) new text endalfentanil;

new text begin (2) new text endalphaprodine;

new text begin (3) new text endanileridine;

new text begin (4) new text endbezitramide;

new text begin (5) bulk dextropropoxyphene (nondosage forms);
new text end

new text begin (6) carfentanil;new text end

new text begin (7) new text enddihydrocodeine;

new text begin (8) new text enddihydromorphinone;

new text begin (9) new text enddiphenoxylate;

new text begin (10) new text endfentanyl;

new text begin (11) new text endisomethadone;

new text begin (12) levo-alpha-acetylmethadol (LAAM)new text end levomethorphan;

new text begin (13) new text endlevorphanol;

new text begin (14) new text endmetazocine;

new text begin (15) new text endmethadone;

new text begin (16) new text endmethadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

new text begin (17) new text endmoramide - intermediate, 2-methyl-3-morpholino-1,
1-diphenyl-propane-carboxylic acid;

new text begin (18) new text endpethidine;

new text begin (19) new text endpethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;

new text begin (20) new text endpethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;

new text begin (21) new text endpethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

new text begin (22) new text endphenazocine;

new text begin (23) new text endpiminodine;

new text begin (24) new text endracemethorphan;

new text begin (25) new text endracemorphannew text begin;
new text end

new text begin (26) remifentanil;
new text end

new text begin (27) sufentanil;
new text end

new text begin (28) tapentadolnew text end.

deleted text begin (3)deleted text endnew text begin (d)new text end Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system:

deleted text begin (a)deleted text endnew text begin (1)new text end amphetamine, its salts, optical isomers, and salts of its optical isomers;

deleted text begin (b)deleted text endnew text begin (2)new text end methamphetamine, its salts, isomers, and salts of its isomers;

deleted text begin (c)deleted text endnew text begin (3)new text end phenmetrazine and its salts;

deleted text begin (d)deleted text endnew text begin (4)new text end methylphenidatenew text begin;
new text end

new text begin (5) lisdexamfetaminenew text end.

deleted text begin (4)deleted text endnew text begin (e)new text end Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including its salts,
isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:

deleted text begin (a) methaqualone
deleted text end

deleted text begin (b)deleted text endnew text begin (1)new text end amobarbitalnew text begin;
new text end

new text begin (2) glutethimide;
new text end

deleted text begin (c)deleted text endnew text begin (3)new text end secobarbitalnew text begin;
new text end

deleted text begin (d)deleted text endnew text begin (4)new text end pentobarbitalnew text begin;
new text end

deleted text begin (e)deleted text endnew text begin (5)new text end phencyclidinenew text begin;
new text end

deleted text begin (f)deleted text endnew text begin (6)new text end phencyclidine immediate precursors:

(i) 1-phenylcyclohexylaminenew text begin;
new text end

(ii) 1-piperidinocyclohexanecarbonitrilenew text begin;
new text end

new text begin (7) phenylacetonenew text end.

new text begin (f) Hallucinogenic substances: nabilone.
new text end

Subd. 4.

Schedule III.

deleted text beginThe following items are listed indeleted text endnew text begin (a)new text end Schedule IIIdeleted text begin:deleted text endnew text begin consists of
the substances listed in this subdivision.
new text end

deleted text begin (1) Any material, compound, mixture, or preparation which contains any quantity of
Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine
and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate;
and which is required by federal law to be labeled with the symbol prescribed by 21 Code
of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that
the drug is listed as a Schedule III controlled substance under federal law.
deleted text end new text begin (b) Stimulants.
Unless specifically excepted or unless listed in another schedule, any material, compound,
mixture, or preparation which contains any quantity of the following substances having
a potential for abuse associated with a stimulant effect on the central nervous system,
including its salts, isomers, and salts of such isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical designation:
new text end

new text begin (1) benzphetamine;
new text end

new text begin (2) chlorphentermine;
new text end

new text begin (3) clortermine;
new text end

new text begin (4) phendimetrazine.
new text end

deleted text begin (2)deleted text endnew text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule,new text end
any material, compound, mixture, or preparation which contains any quantity of the
following substances having a potential for abuse associated with a depressant effect on
the central nervous system:

deleted text begin (a)deleted text endnew text begin (1)new text end any compound, mixture, or preparation containing amobarbital, secobarbital,
pentobarbital or any salt thereof and one or more other active medicinal ingredients which
are not listed in any scheduledeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (b)deleted text endnew text begin (2)new text end any suppository dosage form containing amobarbital, secobarbital,
pentobarbital, or any salt of any of these drugs and approved by the food and drug
administration for marketing only as a suppositorydeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (c)deleted text endnew text begin (3)new text end any substance which contains any quantity of a derivative of barbituric acid,
or any salt of a derivative of barbituric acid, except those substances which are specifically
listed in other schedulesdeleted text begin: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide;
Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.
deleted text endnew text begin;
new text end

deleted text begin (d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of
gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers,
esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers,
esters, and salts is possible within the specific chemical designation.
deleted text end new text begin (4) any drug product
containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers,
for which an application is approved under section 505 of the federal Food, Drug, and
Cosmetic Act;
new text end

new text begin (5) any of the following substances:
new text end

new text begin (i) chlorhexadol;
new text end

new text begin (ii) ketamine, its salts, isomers and salts of isomers;
new text end

new text begin (iii) lysergic acid;
new text end

new text begin (iv) lysergic acid amide;
new text end

new text begin (v) methyprylon;
new text end

new text begin (vi) sulfondiethylmethane;
new text end

new text begin (vii) sulfonenthylmethane;
new text end

new text begin (viii) sulfonmethane;
new text end

new text begin (ix) tiletamine and zolazepam and any salt thereof;
new text end

new text begin (x) embutramide.
new text end

deleted text begin (3) Any material, compound, mixture, or preparation which contains any quantity of
the following substances having a potential for abuse associated with a stimulant effect on
the central nervous system:
deleted text end

deleted text begin (a) Benzphetamine
deleted text end

deleted text begin (b) Chlorphentermine
deleted text end

deleted text begin (c) Clortermine
deleted text end

deleted text begin (d) Mazindol
deleted text end

deleted text begin (e) Phendimetrazine.
deleted text end

deleted text begin (4)deleted text endnew text begin (d)new text end Nalorphine.

deleted text begin (5) Any material, compound, mixture, or preparation containing limited quantities
of any of the following narcotic drugs, or any salts thereof
deleted text endnew text begin (e) Narcotic drugs. Unless
specifically excepted or unless listed in another schedule, any material, compound,
mixture, or preparation containing any of the following narcotic drugs, or their salts
calculated as the free anhydrous base or alkaloid, in limited quantities as follows
new text end:

deleted text begin (a)deleted text end new text begin(1) new text endnot more than 1.80 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
of opiumdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (b)deleted text end new text begin(2) new text endnot more than 1.80 grams of codeine per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (c)deleted text end new text begin(3) new text endnot more than 300 milligrams of dihydrocodeinone per 100 milliliters or
not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an
isoquinoline alkaloid of opiumdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (d)deleted text end new text begin(4) new text endnot more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
in recognized therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (e)deleted text end new text begin(5) new text endnot more than 1.80 grams of dihydrocodeine per 100 milliliters or not more
than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (f)deleted text end new text begin(6) new text endnot more than 300 milligrams of ethylmorphine per 100 milliliters or not more
than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (g)deleted text end new text begin(7) new text endnot more than 500 milligrams of opium per 100 milliliters or per 100 grams,
or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (h)deleted text end new text begin(8) new text endnot more than 50 milligrams of morphine per 100 milliliters or per 100 grams
with one or more active, nonnarcotic ingredients in recognized therapeutic amountsdeleted text begin.deleted text endnew text begin;
new text end

deleted text begin (6)deleted text end new text begin(f) new text end Anabolic steroidsdeleted text begin, whichdeleted text endnew text begin and human growth hormone.
new text end

new text begin (1) Anabolic steroidsnew text end, for purposes of this subdivision, means any drug or
hormonal substance, chemically and pharmacologically related to testosterone, other
than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes:
deleted text begin androstanediol; androstanedione; androstenediol; androstenedione; bolasterone;
boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol;
dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone;
drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human
growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone;
4-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone;
methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b,
17b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane;
17a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone;
methyldienolone; methyltrienolone; methyltestosterone; mibolerone;
17a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate;
norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone;
normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol;
stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone;
trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.
deleted text end

new text begin (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
new text end

new text begin (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
new text end

new text begin (iii) androstanedione (5[alpha]-androstan-3,17-dione);
new text end

new text begin (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;
new text end

new text begin (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
new text end

new text begin (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
new text end

new text begin (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
new text end

new text begin (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
new text end

new text begin (ix) 4-androstenedione (androst-4-en-3,17-dione);
new text end

new text begin (x) 5-androstenedione (androst-5-en-3,17-dione);
new text end

new text begin (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
new text end

new text begin (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
new text end

new text begin (xiii) boldione (androsta-1,4-diene-3,17-dione);
new text end

new text begin (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
new text end

new text begin (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);
new text end

new text begin (xvi) dehydrochloromethyltestosterone
(4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);
new text end

new text begin (xvii) desoxymethyltestosterone
(17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
new text end

new text begin (xviii) [delta]1-dihydrotestosterone-
(17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
new text end

new text begin (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
new text end

new text begin (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
new text end

new text begin (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
new text end

new text begin (xxii) fluoxymesterone
(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
new text end

new text begin (xxiii) formebolone
(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
new text end

new text begin (xxiv) furazabol
(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
-hydroxygon-4-en-3-one;
new text end

new text begin (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
new text end

new text begin (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
new text end

new text begin (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
new text end

new text begin (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
new text end

new text begin (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
new text end

new text begin (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
new text end

new text begin (xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
new text end

new text begin (xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
new text end

new text begin (xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
new text end

new text begin (xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
new text end

new text begin (xxxv) 17[alpha]-methyl-4-hydroxynandrolone
(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (xxxvi) methyldienolone
(17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
new text end

new text begin (xxxvii) methyltrienolone
(17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
new text end

new text begin (xxxviii) methyltestosterone
(17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
new text end

new text begin (xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone
(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
new text end

new text begin (xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
new text end

new text begin (xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
(3[beta],17[beta]-dihydroxyestr-5-ene;
new text end

new text begin (xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
new text end

new text begin (xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
new text end

new text begin (xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
new text end

new text begin (xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
new text end

new text begin (xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
new text end

new text begin (li) oxandrolone
(17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
new text end

new text begin (lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
new text end

new text begin (liii) oxymetholone
(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
new text end

new text begin (liv) stanozolol
(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
new text end

new text begin (lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
new text end

new text begin (lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
lactone);
new text end

new text begin (lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
new text end

new text begin (lviii) tetrahydrogestrinone
(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
new text end

new text begin (lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
new text end

new text begin (lx) any salt, ester, or ether of a drug or substance described in this paragraph.new text end

Anabolic steroids are not included if they are: deleted text begin(i)deleted text endnew text begin (A)new text end expressly intended for administration
through implants to cattle or other nonhuman species; and deleted text begin(ii)deleted text endnew text begin (B)new text end approved by the United
States Food and Drug Administration for that usedeleted text begin.deleted text endnew text begin;
new text end

new text begin (2) Human growth hormones.
new text end

new text begin (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and
encapsulated in a soft gelatin capsule in a United States Food and Drug Administration
approved product.
new text end

new text begin (h) Any material, compound, mixture, or preparation containing the following
narcotic drug or its salt: buprenorphine.
new text end

Subd. 5.

Schedule IV.

deleted text beginThe following items are listed in Schedule IV: Barbital;
Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam;
Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine;
Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with
the following drugs in the following or lower concentrations: conjugated estrogens, 0.4
mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital;
Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine
deleted text endnew text begin (a)
Schedule IV consists of the substances listed in this subdivision
new text end.

new text begin (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
any material, compound, mixture, or preparation containing any of the following narcotic
drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
as follows:
new text end

new text begin (1) not more than one milligram of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit;
new text end

new text begin (2) dextropropoxyphene (Darvon and Darvocet).
new text end

new text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule,
any material, compound, mixture, or preparation containing any quantity of the following
substances, including its salts, isomers, and salts of isomers whenever the existence of the
salts, isomers, and salts of isomers is possible:
new text end

new text begin (1) alprazolam;
new text end

new text begin (2) barbital;
new text end

new text begin (3) bromazepam;
new text end

new text begin (4) camazepam;
new text end

new text begin (5) carisoprodol;
new text end

new text begin (6) chloral betaine;
new text end

new text begin (7) chloral hydrate;
new text end

new text begin (8) chlordiazepoxide;
new text end

new text begin (9) clobazam;
new text end

new text begin (10) clonazepam;
new text end

new text begin (11) clorazepate;
new text end

new text begin (12) clotiazepam;
new text end

new text begin (13) cloxazolam;
new text end

new text begin (14) delorazepam;
new text end

new text begin (15) diazepam;
new text end

new text begin (16) dichloralphenazone;
new text end

new text begin (17) estazolam;
new text end

new text begin (18) ethchlorvynol;
new text end

new text begin (19) ethinamate;
new text end

new text begin (20) ethyl loflazepate;
new text end

new text begin (21) fludiazepam;
new text end

new text begin (22) flurazepam;
new text end

new text begin (23) halazepam;
new text end

new text begin (24) haloxazolam;
new text end

new text begin (25) ketazolam;
new text end

new text begin (26) loprazolam;
new text end

new text begin (27) lorazepam;
new text end

new text begin (28) lormetazepam mebutamate;
new text end

new text begin (29) medazepam;
new text end

new text begin (30) meprobamate;
new text end

new text begin (31) methohexital;
new text end

new text begin (32) methylphenobarbital;
new text end

new text begin (33) midazolam;
new text end

new text begin (34) nimetazepam;
new text end

new text begin (35) nitrazepamnordiazepam;
new text end

new text begin (36) oxazepam;
new text end

new text begin (37) oxazolam;
new text end

new text begin (38) paraldehydepetrichloral;
new text end

new text begin (39) phenobarbital;
new text end

new text begin (40) pinazepam;
new text end

new text begin (41) prazepam;
new text end

new text begin (42) quazepam;
new text end

new text begin (43) temazepam;
new text end

new text begin (44) tetrazepam;
new text end

new text begin (45) triazolam;
new text end

new text begin (46) zaleplon;
new text end

new text begin (47) zolpidem;
new text end

new text begin (48) zopiclone.
new text end

new text begin (d) Any material, compound, mixture, or preparation which contains any quantity of
the following substance including its salts, isomers, and salts of such isomers, whenever
the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
new text end

new text begin (e) Stimulants. Unless specifically excepted or unless listed in another schedule,
any material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system, including its
salts, isomers, and salts of isomers:
new text end

new text begin (1) cathine (norpseudoephedrine);
new text end

new text begin (2) diethylpropion;
new text end

new text begin (3) fencamfamine;
new text end

new text begin (4) fenproporex;
new text end

new text begin (5) mazindol;
new text end

new text begin (6) mefenorex;
new text end

new text begin (7) modafinil;
new text end

new text begin (8) pemoline (including organometallic complexes and chelates thereof);
new text end

new text begin (9) phentermine;
new text end

new text begin (10) pipradol;
new text end

new text begin (11) sibutramine;
new text end

new text begin (12) SPA (1-dimethylamino-1,2-diphenylethane).
new text end

Subd. 6.

Schedule V; restrictions on methamphetamine precursor drugs.

(a) As
used in this subdivision, the following terms have the meanings given:

(1) "methamphetamine precursor drug" means any compound, mixture, or
preparation intended for human consumption containing ephedrine or pseudoephedrine as
its sole active ingredient or as one of its active ingredients; and

(2) "over-the-counter sale" means a retail sale of a drug or product but does not
include the sale of a drug or product pursuant to the terms of a valid prescription.

(b) The following items are listed in Schedule V:

(1) any compound, mixture, or preparation containing any of the following limited
quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
ingredients in sufficient proportion to confer upon the compound, mixture or preparation
valuable medicinal qualities other than those possessed by the narcotic drug alone:

(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
grams;

(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
grams;

(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
of atropine sulfate per dosage unit; deleted text beginor
deleted text end

(iv) not more than deleted text begin15 milligrams of anhydrous morphine per 100 milliliters or per
100 grams; and
deleted text endnew text begin 100 milligrams of opium per 100 milliliters or per 100 grams; or
new text end

new text begin (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit.
new text end

new text begin (2) Stimulants. Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture, or preparation that contains any quantity of
the following substance having a stimulant effect on the central nervous system, including
its salts, isomers, and salts of isomers: pyrovalerone.
new text end

new text begin (3) Depressants. Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture, or preparation that contains any quantity
of the following substance having a depressant effect on the central nervous system,
including its salts, isomers, and salts of isomers:
new text end

new text begin (i) pregabalin;
new text end

new text begin (ii) lacosamide.
new text end

deleted text begin (2)deleted text endnew text begin (4)new text end Any compound, mixture, or preparation containing ephedrine or
pseudoephedrine as its sole active ingredient or as one of its active ingredients.

(c) No person may sell in a single over-the-counter sale more than two packages
of a methamphetamine precursor drug or a combination of methamphetamine precursor
drugs or any combination of packages exceeding a total weight of six grams, calculated as
the base.

(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

(1) packages containing not more than a total of three grams of one or
more methamphetamine precursor drugs, calculated in terms of ephedrine base or
pseudoephedrine base; or

(2) for nonliquid products, sales in blister packs, where each blister contains not
more than two dosage units, or, if the use of blister packs is not technically feasible, sales
in unit dose packets or pouches.

(e) A business establishment that offers for sale methamphetamine precursor drugs
in an over-the-counter sale shall ensure that all packages of the drugs are displayed
behind a checkout counter where the public is not permitted and are offered for sale only
by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
establishment shall ensure that the person making the sale requires the buyer:

(1) to provide photographic identification showing the buyer's date of birth; and

(2) to sign a written or electronic document detailing the date of the sale, the name
of the buyer, and the amount of the drug sold.

A document described under clause (2) must be retained by the establishment for
at least three years and must at all reasonable times be open to the inspection of any
law enforcement agency.

Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
purchase.

(f) No person may acquire through over-the-counter sales more than six grams of
methamphetamine precursor drugs, calculated as the base, within a 30-day period.

(g) No person may sell in an over-the-counter sale a methamphetamine precursor
drug to a person under the age of 18 years. It is an affirmative defense to a charge under
this paragraph if the defendant proves by a preponderance of the evidence that the
defendant reasonably and in good faith relied on proof of age as described in section
340A.503, subdivision 6.

(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
payment of a fine of not more than $1,000, or both.

(i) An owner, operator, supervisor, or manager of a business establishment that
offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
penalties for violating any of those paragraphs if the person:

(1) did not have prior knowledge of, participate in, or direct the employee or agent to
commit the violation; and

(2) documents that an employee training program was in place to provide the
employee or agent with information on the state and federal laws and regulations regarding
methamphetamine precursor drugs.

(j) Any person employed by a business establishment that offers for sale
methamphetamine precursor drugs who sells such a drug to any person in a suspicious
transaction shall report the transaction to the owner, supervisor, or manager of the
establishment. The owner, supervisor, or manager may report the transaction to local law
enforcement. A person who reports information under this subdivision in good faith is
immune from civil liability relating to the report.

(k) Paragraphs (b) to (j) do not apply to:

(1) pediatric products labeled pursuant to federal regulation primarily intended for
administration to children under 12 years of age according to label instructions;

(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
being manufactured in a manner that prevents the drug from being used to manufacture
methamphetamine;

(3) methamphetamine precursor drugs in gel capsule or liquid form; or

(4) compounds, mixtures, or preparations in powder form where pseudoephedrine
constitutes less than one percent of its total weight and is not its sole active ingredient.

(l) The Board of Pharmacy, in consultation with the Department of Public Safety,
shall certify methamphetamine precursor drugs that meet the requirements of paragraph
(k), clause (2), and publish an annual listing of these drugs.

(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
States Drug Enforcement Administration are exempt from the methamphetamine precursor
drug storage requirements of this section.

(n) This section preempts all local ordinances or regulations governing the sale
by a business establishment of over-the-counter products containing ephedrine or
pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.

Subd. 7.

Board of Pharmacy; regulation of substances.

The Board of Pharmacy
is authorized to regulate and define additional substances which contain quantities of a
substance possessing abuse potential in accordance with the following criteria:

(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the
substance has: A high potential for abuse, no currently accepted medical use in the United
States, and a lack of accepted safety for use under medical supervision.

(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the
substance has: A high potential for abuse, currently accepted medical use in the United
States, or currently accepted medical use with severe restrictions, and that abuse may lead
to severe psychological or physical dependence.

(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the
substance has: A potential for abuse less than the substances listed in Schedules I and II,
currently accepted medical use in treatment in the United States, and that abuse may lead
to moderate or low physical dependence or high psychological dependence.

(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that
the substance has: A low potential for abuse relative to the substances in Schedule III,
currently accepted medical use in treatment in the United States, and that abuse may lead
to limited physical dependence or psychological dependence relative to the substances in
Schedule III.

(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the
substance has: A low potential for abuse relative to the substances listed in Schedule IV,
currently accepted medical use in treatment in the United States, and limited physical
dependence and/or psychological dependence liability relative to the substances listed
in Schedule IV.

Subd. 8.

Add, delete, or reschedule substances.

The state Board of Pharmacy may,
by rule, add substances to or delete or reschedule substances listed in this section. The
Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as
provided in subdivision 12.

In making a determination regarding a substance, the Board of Pharmacy shall
consider the following: The actual or relative potential for abuse, the scientific evidence
of its pharmacological effect, if known, the state of current scientific knowledge
regarding the substance, the history and current pattern of abuse, the scope, duration,
and significance of abuse, the risk to public health, the potential of the substance to
produce psychic or physiological dependence liability, and whether the substance is an
immediate precursor of a substance already controlled under this section. The state Board
of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal
use in a schedule only if such drug must, under either federal or state law or rule, be
sold only on prescription.

deleted text begin Subd. 8a. deleted text end

deleted text begin Methamphetamine precursors deleted text end deleted text begin . deleted text end

deleted text begin The State Board of Pharmacy may,
by order, require that nonprescription ephedrine or pseudophedrine products sold in
gel capsule or liquid form be subject to the sale restrictions established in subdivision
6 for methamphetamine precursor drugs, if the board concludes that ephedrine or
pseudophedrine products in gel capsule or liquid form can be used to manufacture
methamphetamine. In assessing the need for an order under this subdivision, the board
shall consult at least annually with the advisory council on controlled substances, the
commissioner of public safety, and the commissioner of health.
deleted text end

Subd. 9.

Except substances by rule.

The state Board of Pharmacy may by rule
except any compound, mixture, or preparation containing any stimulant or depressant
substance listed in subdivision 4, deleted text beginclauses (1) and (2)deleted text endnew text begin paragraphs (b) and (c),new text end or in
subdivisions 5 and 6 from the application of all or any part of this chapter, if the
compound, mixture, or preparation contains one or more active medicinal ingredients not
having a stimulant or depressant effect on the central nervous system; provided, that
such admixtures shall be included therein in such combinations, quantity, proportion,
or concentration as to vitiate the potential for abuse of the substances which do have a
stimulant or depressant effect on the central nervous system.

Subd. 10.

Dextromethorphan.

Dextromethorphan shall not be deemed to be
included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless
controlled pursuant to the foregoing provisions of this section.

Subd. 12.

Coordination of controlled substance regulation with federal law and
state statute.

If any substance is designated, rescheduled, or deleted as a controlled
substance under federal law and notice thereof is given to the state Board of Pharmacy, the
state Board of Pharmacy shall similarly control the substance under this chapter, after the
expiration of 30 days from publication in the Federal Register of a final order designating
a substance as a controlled substance or rescheduling or deleting a substance. Such order
shall be filed with the secretary of state. If within that 30-day period, the state Board of
Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for
objection and afford all interested parties an opportunity to be heard. At the conclusion of
the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject
to the provisions of chapter 14.

In exercising the authority granted by this chapter, the state Board of Pharmacy shall
be subject to the provisions of chapter 14. deleted text beginThe state Board of Pharmacy shall provide
copies of any proposed rule under this chapter to the advisory council on controlled
substances at least 30 days prior to any hearing required by section 14.14, subdivision 1.
The state Board of Pharmacy shall consider the recommendations of the advisory council
on controlled substances, which may be made prior to or at the hearing.
deleted text end

The state Board of Pharmacy shall annually submit a report to the legislature on or
before December 1 that specifies what changes the board made to the controlled substance
schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in
the preceding 12 months. The report must include specific recommendations for amending
the controlled substance schedules contained in subdivisions 2 to 6, so that they conform
with the controlled substance schedules maintained by the board in Minnesota Rules,
parts 6800.4210 to 6800.4250.

deleted text begin Subd. 13. deleted text end

deleted text begin Implementation study. deleted text end

deleted text begin Annually, the state Board of Pharmacy shall study
the implementation of this chapter in relation to the problems of drug abuse in Minnesota.
deleted text end

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective August 1, 2012, and applies to crimes
committed on or after that date.
new text end

Sec. 2.

Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is
amended to read:


Subd. 6.

Sale or possession of synthetic cannabinoids.

(a) As used in this
subdivision, "synthetic cannabinoid" includes any substance included in section 152.02,
subdivision 2, new text beginparagraph (h), new text endclause deleted text begin(7)deleted text endnew text begin (3)new text end.

(b) new text beginA person who unlawfully sells a synthetic cannabinoid for no remuneration is
guilty of a gross misdemeanor.
new text end

new text begin (c) new text endA person who unlawfully sells deleted text beginany amount ofdeleted text end a synthetic cannabinoid is guilty of
a deleted text begingross misdemeanordeleted text endnew text begin felony and if convicted may be sentenced to imprisonment for not
more than five years or to payment of a fine of not more than $10,000, or both
new text end.

deleted text begin (c)deleted text endnew text begin (d)new text end A person who unlawfully possesses any amount of a synthetic cannabinoid is
guilty of a misdemeanor.

deleted text begin (d)deleted text endnew text begin (e)new text end Notwithstanding any contrary provision in sections 152.021 to 152.025, this
subdivision describes the exclusive penalties for the sale and possession of synthetic
cannabinoid.

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective August 1, 2012, and applies to crimes
committed on or after that date.
new text end